Kaiser Permanente & Halcyon's 2026 Health Innovation Spotlight

You are cordially invited to our 2026 Health Innovation Spotlight, an evening bringing together healthcare leaders, social impact investors, and entrepreneurs working in health equity and innovation. Join us as we feature solutions from our newest cohort of health entrepreneurs and engage in a panel discussion on the future of health innovation. Agenda 5:30 PM: Doors Open – Networking & Refreshments 6:00 PM: Opening Remarks – Welcome from Halcyon & Kaiser Permanente Leadership 6:15 PM – 6:45 PM: Panel Discussion – Insights from Industry Leaders on Health Equity & Innovation 6:45 PM – 7:00 PM: Fellow Pitches – Pitches from Featured Health Cohort Startups 7:00 PM – 7:30 PM: Networking & Closing – Connect with Founders, Leaders, and Fellow Attendees Featured Cohort & Fellows: Below are the featured ventures in this year's 2026 US Health Accelerator Cohort. Conceivable (Kirsten Karchmer) – Conceivable is an operating system for women's reproductive health delivering AI-powered clinical care through a 24/7 team of specialized agents at a fraction of the cost of conventional IVF, designed to support women conventional fertility medicine never reaches across nine reproductive life stages. Cove (McCall Brinskele) – Cove is a medical device company developing a standardized at-home menstrual fluid collection system for diagnostics and regenerative medicine. Their platform enables researchers and clinicians to access a previously untapped biological sample type with consistent, research-grade quality. Freyya, Inc. (Gabriele G. Niederauer) – Freyya, Inc. is a wearable biofeedback platform that provides real-time monitoring during everyday activities, enabling clinicians to remotely guide therapy, improve adherence, expand access to care, and deliver objective data that supports better treatment outcomes for women suffering from pelvic floor disorders. Gisens Biotech (Luis Pierpauli) – Gisens Biotech is replacing periodic lab snapshots with real-time, non-invasive biomarker mo